Dr. Mamounas on Extended Letrozole Therapy for Breast Cancer

Terry P. Mamounas, MD, MPH, FACS
Published: Wednesday, Jan 11, 2017



Eleftherios (Terry) P. Mamounas, MD, medical director of the Comprehensive Breast Program at the University of Florida Health Cancer Center, discusses the phase III trial for extended letrozole (Femara) therapy for patients with breast cancer.

The NASBP B-42 trial evaluated the role of letrozole for patients with stage I to IIIA breast cancer that had received 5 years of an aromatase inhibitor (AI) or the combination of tamoxifen (Nolvadex) followed by an AI. Patients who were disease free after 5 years of these treatments were given either letrozole or a placebo for the randomized study.

The primary endpoints of the study were to prevent breast cancer recurrence and cancer appearing in the opposite breast. The secondary endpoints include breast cancer-free interval, distant recurrence, and an assessment of toxicity in terms of osteoporotic fractures as well as arterial thrombotic events.

SELECTED
LANGUAGE


Eleftherios (Terry) P. Mamounas, MD, medical director of the Comprehensive Breast Program at the University of Florida Health Cancer Center, discusses the phase III trial for extended letrozole (Femara) therapy for patients with breast cancer.

The NASBP B-42 trial evaluated the role of letrozole for patients with stage I to IIIA breast cancer that had received 5 years of an aromatase inhibitor (AI) or the combination of tamoxifen (Nolvadex) followed by an AI. Patients who were disease free after 5 years of these treatments were given either letrozole or a placebo for the randomized study.

The primary endpoints of the study were to prevent breast cancer recurrence and cancer appearing in the opposite breast. The secondary endpoints include breast cancer-free interval, distant recurrence, and an assessment of toxicity in terms of osteoporotic fractures as well as arterial thrombotic events.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x